These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 1397745)

  • 41. [A randomized, comparative study of rabeprazole vs. ranitidine maintenance therapies for reflux esophagitis--multicenter study].
    Jee SR; Seol SY; Kim DH; Park SJ; Han SY; Urm SH; Lee JT
    Korean J Gastroenterol; 2005 May; 45(5):321-7. PubMed ID: 15908764
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Therapy with omeprazole in patients with peptic ulcerations resistant to extended high-dose ranitidine treatment.
    Brunner G; Creutzfeldt W; Harke U; Lamberts R
    Digestion; 1988; 39(2):80-90. PubMed ID: 3410170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Short and long-term effect of two different dosages of ranitidine in the therapy of reflux oesophagitis.
    Pace F; Sangaletti O; Bianchi Porro G
    Ital J Gastroenterol; 1990 Feb; 22(1):28-32. PubMed ID: 2131925
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Omeprazole versus ranitidine or ranitidine/metoclopramide in poorly responsive symptomatic gastroesophageal reflux disease.
    Richter JE; Sabesin SM; Kogut DG; Kerr RM; Wruble LD; Collen MJ
    Am J Gastroenterol; 1996 Sep; 91(9):1766-72. PubMed ID: 8792695
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of ranitidine and cisapride in the treatment of reflux oesophagitis.
    McKenna CJ; Mills JG; Goodwin C; Wood JR
    Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):817-22. PubMed ID: 8574711
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of omeprazole and high doses of ranitidine on gastric acidity and gastroesophageal reflux in patients with moderate-severe esophagitis.
    Fiorucci S; Santucci L; Morelli A
    Am J Gastroenterol; 1990 Nov; 85(11):1458-62. PubMed ID: 2239873
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Omeprazole versus ranitidine in erosive oesophagitis.
    Zeitoun P; Desjars De Keranroué N; Isal JP
    Lancet; 1987 Sep; 2(8559):621-2. PubMed ID: 2887900
    [No Abstract]   [Full Text] [Related]  

  • 48. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of omeprazole in reflux oesophagitis.
    Dent J; Hetzel DJ; MacKinnon MA; Reed WD; Narielvala FM
    Scand J Gastroenterol Suppl; 1989; 166():76-82; discussion 94. PubMed ID: 2690334
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Double blind comparison of omeprazole (40 mg od) versus cimetidine (400 mg qd) in the treatment of symptomatic erosive reflux oesophagitis, assessed endoscopically, histologically and by 24 h pH monitoring.
    Dehn TC; Shepherd HA; Colin-Jones D; Kettlewell MG; Carroll NJ
    Gut; 1990 May; 31(5):509-13. PubMed ID: 2190864
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Omeprazole in the therapy of acid-induced diseases].
    Simon B; Dammann HG; Müller P
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Reduced suppression of gastric acid by ranitidine in severe reflux esophagitis. A pilot study].
    Koop H; Klein M; Bauer A; Arnold R
    Z Gastroenterol; 1988 Jul; 26(7):345-50. PubMed ID: 3223004
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Erosive oesophagitis: outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo.
    Bardhan KD; Cherian P; Vaishnavi A; Jones RB; Thompson M; Morris P; Brooks A; D'Silva J; Gillon KR; Wason C; Patterson J; Polak J; Bishop A
    Gut; 1998 Oct; 43(4):458-64. PubMed ID: 9824569
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety.
    Klinkenberg-Knol EC; Festen HP; Jansen JB; Lamers CB; Nelis F; Snel P; Lückers A; Dekkers CP; Havu N; Meuwissen SG
    Ann Intern Med; 1994 Aug; 121(3):161-7. PubMed ID: 8017742
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Short-term treatment of reflux oesophagitis with ranitidine 300 mg nocte. Italian multicentre study.
    Bovero E; Cheli R; Barbara L; Baldi F; Boero A; Mura GC; Camarri E; Corradini P; Dobrilla G; Piazzi L
    Hepatogastroenterology; 1987 Aug; 34(4):155-9. PubMed ID: 3311954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Omeprazole in the long-term management of patients with acid-related diseases resistant to ranitidine.
    Brunner G; Creutzfeldt W
    Scand J Gastroenterol Suppl; 1989; 166():101-5; discussion 111-3. PubMed ID: 2513641
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Results of a Scandinavian multicentre trial.
    Hatlebakk JG; Berstad A; Carling L; Svedberg LE; Unge P; Ekström P; Halvorsen L; Stallemo A; Hovdenak N; Trondstad R
    Scand J Gastroenterol; 1993 Mar; 28(3):224-8. PubMed ID: 8446846
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group.
    Castell DO; Richter JE; Robinson M; Sontag SJ; Haber MM
    Am J Gastroenterol; 1996 Sep; 91(9):1749-57. PubMed ID: 8792693
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Ranitidine, 150 mg three times a day, in the treatment of reflux oesophagitis. A placebo-controlled, double-blind study.
    Lehtola J; Niemelä S; Martikainen J; Krekelä I
    Scand J Gastroenterol; 1986 Mar; 21(2):175-80. PubMed ID: 3520796
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
    Feldman M; Harford WV; Fisher RS; Sampliner RE; Murray SB; Greski-Rose PA; Jennings DE
    Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.